Xianju Pharma's Progesterone Injection Passes Generic Drug Consistency Evaluation

GateNews
Xianju Pharmaceutical announced on May 26 that it received approval from China's National Medical Products Administration for its progesterone injection (1ml:50mg) through generic drug consistency evaluation, with approval notice number 2026B03041. The approved formulation contains 50mg of progesterone per vial and is indicated for treating menstrual disorders, luteal insufficiency, threatened miscarriage, and luteal phase syndrome, as well as luteal supplementation in assisted reproductive technologies.
Disclaimer: The information on this page may come from third-party sources and is for reference only. It does not represent the views or opinions of Gate and does not constitute any financial, investment, or legal advice. Virtual asset trading involves high risk. Please do not rely solely on the information on this page when making decisions. For details, see the Disclaimer.
Comment
0/400
No comments